MedTrace Logo

Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy

NCT01049399 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2012-01-05

No results posted yet for this study

Summary

The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy

Conditions

Interventions

DRUG

tideglusib

800 mg of tideglusib as a powder for oral suspension once daily in fasting conditions for 52 weeks

DRUG

tideglusib

600 mg of tideglusib as a powder for oral suspension, administered once daily in fasting conditions for 52 weeks

DRUG

placebo

powder for oral suspension administered once daily in fasting conditions for 52 weeks

Sponsors & Collaborators

  • i3 Research

    collaborator INDUSTRY

  • Noscira SA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-09-30
Completion
2011-11-30

Countries

  • United States
  • Germany
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01049399 on ClinicalTrials.gov